Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Asia Pacific Hormone Refractory Breast Cancer Market by TREATMENT (Tumor Markers Therapy, Gene Expression Therapy, Gene Mutation Therapy, Others) and by Application (Scientific Research and Production, Medical Technology, Biological Science and Technology, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A01037

Pages: NA

Charts: NA

Tables: NA

Breast cancer is the most common type of malignant cancer prevalent in women above the age of 40. According to the estimates of World Health Organization, cancer is the most fatal human disease accounting for the deaths of ~8.2 million people worldwide in 2012. Among these deaths, breast cancer was found to be most prominent disease among women that killed ~521,000 individuals. Presently, increasing number of hormone therapies have made refractory breast cancers resistant toward therapeutics, termed as hormone-resistant breast cancers. However, recently developed hormone refractory breast cancer chemotherapeutic agents such as, trastuzumab and everolimus, alone or in combination, are under clinical trials for the effective treatment of hormone refractory breast cancers.

Key factors responsible for the growth of this market involve increasing incidences of breast cancers, aging population, demands of advanced therapeutics, increasing prevalence of hormone refractory breast cancers, and the presence of a significant number of anticancer pipeline drugs. Rising life span of cancer-affected population is one of the other factors responsible for the growth of this market. However, social stigma of testing breast cancer lacks technological reach. Insufficient advanced chemotherapeutic treatments restraining the hormone refractory breast cancer market. Substantial number of new chemical entities (NCEs) in various phases of clinical trials will emerge as potential opportunities in the Asia Pacific market.

The Asia Pacific hormone refractory breast cancer market is segmented into China, Japan, India, Australia and others. The Asia-Pacific region is expected to rise at the significant pace, owing to rapid growth of pharmaceutical and healthcare industry along with the improved purchasing power of the service providers in this region. Rapidly emerging economies and the rise of medical tourism in regions such as India and China, will drive the growth of hormone refractory breast cancer market. Rising kidney failure, prevalence rates, in the Asia-Pacific regions should boost the growth of this market.

KEY BENEFITS

  • The analysis, made in this report, helps in understanding the strategies adopted by various companies for gaining market share in hormone refractory breast cancer market
  • This report provides a comprehensive analysis of factors that drive and restrict the growth of the hormone refractory breast cancer market
  • Detailed study of the strategies of key leaders, partnerships, and acquisitions in the Asia Pacific hormone refractory breast cancer market would be informative for professionals in the corporate sector
  • Pin-point analysis of geographic segments helps to identify opportunities for growth within the hormone refractory breast cancer market
  • An analysis for the market attractiveness has been included for therapeutics, devices, and geographic regions along with a detailed analysis of factors responsible for the rapid growth of the market segments
  • Ease of doing business analysis should help in making strategic business decisions

ASIA-PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET KEY SEGMENTS

BY TREATMENT MODALITY

  • Hormone receptor-based therapy
  • Tumor markers therapy
  • Gene expression therapy
  • Gene mutation therapy

BY GEOGRAPHY

  • China
  • Japan
  • India
  • Australia
  • Others

 Key Market Segments

  • By TREATMENT
    • Tumor Markers Therapy
    • Gene Expression Therapy
    • Gene Mutation Therapy
    • Others
  • By Application
    • Scientific Research and Production
    • Medical Technology
    • Biological Science and Technology
    • Others
  • By Region
    • North America
      • UNITED STATES
      • CANADA
      • MEXICO
    • Europe
      • FRANCE
      • GERMANY
      • ITALY
      • SPAIN
      • UNITED KINGDOM
      • Rest of Europe
    • Asia-Pacific
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • AUSTRALIA
      • Rest of Asia Pacific
    • LAMEA
      • Brazil
      • South Africa,
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Anant Pharmaceuticals Pvt. Ltd.
  • Fresenius Kabi
  • Boehringer Ingelheim GmbH
  • Neopharm
  • AmpliMed Corporation
  • AstraZeneca
  • Bluefish Pharmaceuticals AB
  • Sanofi Genzyme
  • NeoCorp GmbH
  • F. Hoffmann La Roche

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET, BY TREATMENT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment

    • 4.2. Tumor Markers Therapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Gene Expression Therapy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Gene Mutation Therapy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Scientific Research And Production

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Medical Technology

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Biological Science And Technology

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Treatment

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S.

        • 6.2.5.1 Market size and forecast, treatment

        • 6.2.5.2 Market size and forecast, application

      • 6.2.6. Canada

        • 6.2.6.1 Market size and forecast, treatment

        • 6.2.6.2 Market size and forecast, application

      • 6.2.7. Mexico

        • 6.2.7.1 Market size and forecast, treatment

        • 6.2.7.2 Market size and forecast, application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Treatment

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France

        • 6.3.5.1 Market size and forecast, treatment

        • 6.3.5.2 Market size and forecast, application

      • 6.3.6. Germany

        • 6.3.6.1 Market size and forecast, treatment

        • 6.3.6.2 Market size and forecast, application

      • 6.3.7. Italy

        • 6.3.7.1 Market size and forecast, treatment

        • 6.3.7.2 Market size and forecast, application

      • 6.3.8. Spain

        • 6.3.8.1 Market size and forecast, treatment

        • 6.3.8.2 Market size and forecast, application

      • 6.3.9. UK

        • 6.3.9.1 Market size and forecast, treatment

        • 6.3.9.2 Market size and forecast, application

      • 6.3.10. Russia

        • 6.3.10.1 Market size and forecast, treatment

        • 6.3.10.2 Market size and forecast, application

      • 6.3.11. Rest Of Europe

        • 6.3.11.1 Market size and forecast, treatment

        • 6.3.11.2 Market size and forecast, application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Treatment

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China

        • 6.4.5.1 Market size and forecast, treatment

        • 6.4.5.2 Market size and forecast, application

      • 6.4.6. Japan

        • 6.4.6.1 Market size and forecast, treatment

        • 6.4.6.2 Market size and forecast, application

      • 6.4.7. India

        • 6.4.7.1 Market size and forecast, treatment

        • 6.4.7.2 Market size and forecast, application

      • 6.4.8. South Korea

        • 6.4.8.1 Market size and forecast, treatment

        • 6.4.8.2 Market size and forecast, application

      • 6.4.9. Australia

        • 6.4.9.1 Market size and forecast, treatment

        • 6.4.9.2 Market size and forecast, application

      • 6.4.10. Thailand

        • 6.4.10.1 Market size and forecast, treatment

        • 6.4.10.2 Market size and forecast, application

      • 6.4.11. Malaysia

        • 6.4.11.1 Market size and forecast, treatment

        • 6.4.11.2 Market size and forecast, application

      • 6.4.12. Indonesia

        • 6.4.12.1 Market size and forecast, treatment

        • 6.4.12.2 Market size and forecast, application

      • 6.4.13. Rest of Asia Pacific

        • 6.4.13.1 Market size and forecast, treatment

        • 6.4.13.2 Market size and forecast, application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Treatment

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil

        • 6.5.5.1 Market size and forecast, treatment

        • 6.5.5.2 Market size and forecast, application

      • 6.5.6. South Africa

        • 6.5.6.1 Market size and forecast, treatment

        • 6.5.6.2 Market size and forecast, application

      • 6.5.7. Saudi Arabia

        • 6.5.7.1 Market size and forecast, treatment

        • 6.5.7.2 Market size and forecast, application

      • 6.5.8. UAE

        • 6.5.8.1 Market size and forecast, treatment

        • 6.5.8.2 Market size and forecast, application

      • 6.5.9. Argentina

        • 6.5.9.1 Market size and forecast, treatment

        • 6.5.9.2 Market size and forecast, application

      • 6.5.10. Rest of LAMEA

        • 6.5.10.1 Market size and forecast, treatment

        • 6.5.10.2 Market size and forecast, application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. AstraZeneca

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. AmpliMed Corporation

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. F. Hoffmann La Roche

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Bluefish Pharmaceuticals AB

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. NeoCorp GmbH

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Neopharm

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Sanofi Genzyme

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Boehringer Ingelheim GmbH

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Anant Pharmaceuticals Pvt. Ltd.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Fresenius Kabi

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 2. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR TUMOR MARKERS THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE EXPRESSION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE MUTATION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 7. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR SCIENTIFIC RESEARCH AND PRODUCTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR MEDICAL TECHNOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR BIOLOGICAL SCIENCE AND TECHNOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 15. U.S. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 16. U.S. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. CANADA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 18. CANADA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 20. MEXICO ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. ITALY ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 29. ITALY ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. UK ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 33. UK ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. RUSSIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 35. RUSSIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 41. CHINA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 42. CHINA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 44. JAPAN ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. INDIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 46. INDIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 48. SOUTH KOREA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 50. AUSTRALIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. THAILAND ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 52. THAILAND ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. MALAYSIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 54. MALAYSIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. INDONESIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 56. INDONESIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 63. BRAZIL ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH AFRICA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH AFRICA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. SAUDI ARABIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 67. SAUDI ARABIA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. UAE ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 69. UAE ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. ARGENTINA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 71. ARGENTINA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. REST OF LAMEA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 73. REST OF LAMEA ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 75. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 76. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 77. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 78. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. AMPLIMED CORPORATION: KEY EXECUTIVES
  • TABLE 80. AMPLIMED CORPORATION: COMPANY SNAPSHOT
  • TABLE 81. AMPLIMED CORPORATION: OPERATING SEGMENTS
  • TABLE 82. AMPLIMED CORPORATION: PRODUCT PORTFOLIO
  • TABLE 83. AMPLIMED CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. F. HOFFMANN LA ROCHE: KEY EXECUTIVES
  • TABLE 85. F. HOFFMANN LA ROCHE: COMPANY SNAPSHOT
  • TABLE 86. F. HOFFMANN LA ROCHE: OPERATING SEGMENTS
  • TABLE 87. F. HOFFMANN LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 88. F. HOFFMANN LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. BLUEFISH PHARMACEUTICALS AB: KEY EXECUTIVES
  • TABLE 90. BLUEFISH PHARMACEUTICALS AB: COMPANY SNAPSHOT
  • TABLE 91. BLUEFISH PHARMACEUTICALS AB: OPERATING SEGMENTS
  • TABLE 92. BLUEFISH PHARMACEUTICALS AB: PRODUCT PORTFOLIO
  • TABLE 93. BLUEFISH PHARMACEUTICALS AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. NEOCORP GMBH: KEY EXECUTIVES
  • TABLE 95. NEOCORP GMBH: COMPANY SNAPSHOT
  • TABLE 96. NEOCORP GMBH: OPERATING SEGMENTS
  • TABLE 97. NEOCORP GMBH: PRODUCT PORTFOLIO
  • TABLE 98. NEOCORP GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. NEOPHARM: KEY EXECUTIVES
  • TABLE 100. NEOPHARM: COMPANY SNAPSHOT
  • TABLE 101. NEOPHARM: OPERATING SEGMENTS
  • TABLE 102. NEOPHARM: PRODUCT PORTFOLIO
  • TABLE 103. NEOPHARM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. SANOFI GENZYME: KEY EXECUTIVES
  • TABLE 105. SANOFI GENZYME: COMPANY SNAPSHOT
  • TABLE 106. SANOFI GENZYME: OPERATING SEGMENTS
  • TABLE 107. SANOFI GENZYME: PRODUCT PORTFOLIO
  • TABLE 108. SANOFI GENZYME: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
  • TABLE 110. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
  • TABLE 111. BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
  • TABLE 112. BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
  • TABLE 113. BOEHRINGER INGELHEIM GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. ANANT PHARMACEUTICALS PVT. LTD.: KEY EXECUTIVES
  • TABLE 115. ANANT PHARMACEUTICALS PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 116. ANANT PHARMACEUTICALS PVT. LTD.: OPERATING SEGMENTS
  • TABLE 117. ANANT PHARMACEUTICALS PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 118. ANANT PHARMACEUTICALS PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. FRESENIUS KABI: KEY EXECUTIVES
  • TABLE 120. FRESENIUS KABI: COMPANY SNAPSHOT
  • TABLE 121. FRESENIUS KABI: OPERATING SEGMENTS
  • TABLE 122. FRESENIUS KABI: PRODUCT PORTFOLIO
  • TABLE 123. FRESENIUS KABI: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 3. SEGMENTATION ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 11. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET SEGMENTATION, TREATMENT
  • FIGURE 12. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR TUMOR MARKERS THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE EXPRESSION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR GENE MUTATION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET SEGMENTATION, APPLICATION
  • FIGURE 17. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR SCIENTIFIC RESEARCH AND PRODUCTION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR MEDICAL TECHNOLOGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR BIOLOGICAL SCIENCE AND TECHNOLOGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: ASIA PACIFIC HORMONE REFRACTORY BREAST CANCER MARKET
  • FIGURE 27. TOP PLAYER POSITIONING,2022
  • FIGURE 28. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. ASTRAZENECA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. AMPLIMED CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. AMPLIMED CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. AMPLIMED CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. F. HOFFMANN LA ROCHE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. F. HOFFMANN LA ROCHE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. F. HOFFMANN LA ROCHE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. BLUEFISH PHARMACEUTICALS AB: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. BLUEFISH PHARMACEUTICALS AB: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. BLUEFISH PHARMACEUTICALS AB: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. NEOCORP GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. NEOCORP GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. NEOCORP GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. NEOPHARM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. NEOPHARM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. NEOPHARM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. SANOFI GENZYME: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. SANOFI GENZYME: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. SANOFI GENZYME: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. BOEHRINGER INGELHEIM GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. ANANT PHARMACEUTICALS PVT. LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. ANANT PHARMACEUTICALS PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. ANANT PHARMACEUTICALS PVT. LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. FRESENIUS KABI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. FRESENIUS KABI: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. FRESENIUS KABI: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
Asia Pacific Hormone Refractory Breast Cancer Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved